TY - JOUR
T1 - A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection
AU - COVID Human Genetic Effort
AU - Casanova, Jean Laurent
AU - Su, Helen C.
AU - Abel, Laurent
AU - Aiuti, Alessandro
AU - Almuhsen, Saleh
AU - Arias, Andres Augusto
AU - Bastard, Paul
AU - Biggs, Catherine
AU - Bogunovic, Dusan
AU - Boisson, Bertrand
AU - Boisson-Dupuis, Stephanie
AU - Bolze, Alexandre
AU - Bondarenko, Anastasia
AU - Bousfiha, Aziz
AU - Brodin, Petter
AU - Bustamante, Jacinta
AU - Butte, Manish
AU - Casari, Giorgio
AU - Ciancanelli, Michael
AU - Cobat, Aurelie
AU - Condino-Neto, Antonio
AU - Cooper, Megan
AU - Dalgard, Clifton
AU - Espinosa, Sara
AU - Feldman, Hagit
AU - Fellay, Jacques
AU - Franco, Jose Luis
AU - Hagin, David
AU - Itan, Yuval
AU - Jouanguy, Emmanuelle
AU - Lucas, Carrie
AU - Mansouri, Davood
AU - Meyts, Isabelle
AU - Milner, Joshua
AU - Mogensen, Trine
AU - Morio, Tomohiro
AU - Ng, Lisa
AU - Notarangelo, Luigi D.
AU - Okada, Satoshi
AU - Ozcelik, Tayfun
AU - Palacín, Pere Soler
AU - Planas, Anna
AU - Prando, Carolina
AU - Puel, Anne
AU - Pujol, Aurora
AU - Redin, Claire
AU - Renia, Laurent
AU - Rodriguez Gallego, Jose Carlos
AU - Quintana-Murci, Lluis
AU - Sancho-Shimizu, Vanessa
N1 - Funding Information:
J.L.C. was supported by funding from the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (UL1TR001866 and R01AI088364), the French National Research Agency (ANR) “Investments for the Future” program (ANR-10-IAHU-01), Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX-62-IBEID), French Foundation for Medical Research (FRM) (EQU201903007798), Institut National de la Santé et de la Recherche Médicale (INSERM), and the University of Paris. H.C.S. was supported by funds from the Division of Intramural Research in the National Institute of Allergy and Infections Diseases, NIH. We thank Yelena Nemirovskaya for editorial assistance. Helen Su holds Adjunct Faculty position in the Department of Pathology and Laboratory Medicine, University of Pennsylvania.
Funding Information:
J.L.C. was supported by funding from the Howard Hughes Medical Institute , the Rockefeller University , the St. Giles Foundation , the National Institutes of Health (NIH) ( UL1TR001866 and R01AI088364 ), the French National Research Agency (ANR) “Investments for the Future” program ( ANR-10-IAHU-01 ), Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases ( ANR-10-LABX-62-IBEID ), French Foundation for Medical Research (FRM) ( EQU201903007798 ), Institut National de la Santé et de la Recherche Médicale (INSERM), and the University of Paris . H.C.S. was supported by funds from the Division of Intramural Research in the National Institute of Allergy and Infections Diseases, NIH . We thank Yelena Nemirovskaya for editorial assistance.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/6/11
Y1 - 2020/6/11
N2 - SARS-CoV-2 infection displays immense inter-individual clinical variability, ranging from silent infection to lethal disease. The role of human genetics in determining clinical response to the virus remains unclear. Studies of outliers—individuals remaining uninfected despite viral exposure and healthy young patients with life-threatening disease—present a unique opportunity to reveal human genetic determinants of infection and disease.
AB - SARS-CoV-2 infection displays immense inter-individual clinical variability, ranging from silent infection to lethal disease. The role of human genetics in determining clinical response to the virus remains unclear. Studies of outliers—individuals remaining uninfected despite viral exposure and healthy young patients with life-threatening disease—present a unique opportunity to reveal human genetic determinants of infection and disease.
UR - http://www.scopus.com/inward/record.url?scp=85085371010&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2020.05.016
DO - 10.1016/j.cell.2020.05.016
M3 - Comment/debate
C2 - 32405102
AN - SCOPUS:85085371010
SN - 0092-8674
VL - 181
SP - 1194
EP - 1199
JO - Cell
JF - Cell
IS - 6
ER -